Back to Search
Start Over
Balancing Prolonged Survival with QoL Using Low-dose Pazopanib Maintenance: A Comparison with the PALETTE Study.
- Source :
-
Anticancer research [Anticancer Res] 2016 Jun; Vol. 36 (6), pp. 2893-7. - Publication Year :
- 2016
-
Abstract
- Background: A consensus has not been reached regarding the optimal pazopanib dosing schedule, which we determined in patients who received pazopanib at our Institution.<br />Patients and Methods: Twenty-five patients who were prescribed pazopanib between 2012 and 2015 were included in this retrospective analysis.<br />Results: The median progression-free survival (PFS) time was 7.7 months. This time (various doses) was similar to that achieved by high-dose pazopanib in the PALETTE study. The log-rank test revealed no significant differences in the PFS times between the low- and high-dose pazopanib groups, with the majority of patients receiving a dose of 400 mg, indicating that controlling the side-effects might be more critical than administering higher doses.<br />Conclusion: Pazopanib should be started from a low dose with careful increase to avoid pazopanib-related side-effects, which is necessary to provide a balance between the life-prolonging effects of pazopanib and quality of life (QoL) of patients.<br /> (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Female
Histiocytoma, Malignant Fibrous mortality
Histiocytoma, Malignant Fibrous psychology
Humans
Indazoles
Male
Middle Aged
Pyrimidines administration & dosage
Pyrimidines adverse effects
Retrospective Studies
Sarcoma mortality
Sarcoma psychology
Sulfonamides administration & dosage
Sulfonamides adverse effects
Angiogenesis Inhibitors therapeutic use
Histiocytoma, Malignant Fibrous drug therapy
Pyrimidines therapeutic use
Quality of Life
Sarcoma drug therapy
Sulfonamides therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1791-7530
- Volume :
- 36
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Anticancer research
- Publication Type :
- Academic Journal
- Accession number :
- 27272802